Watertown-based Dicerna Raises $25M

Watertown, Mass. -- Dicerna Pharmaceuticals, a Watertown-based developer of RNA interference (RNAi) technology for gene silencing, has raised $25 million in its second round of venture capital, which was led by Domain Associates. Founded in 2007, Dicerna Pharmaceuticals is developing new therapeutic agents and drug delivery systems for multiple disease areas. Dicerna has a major alliance with Kyowa Hakko Kirin for DsiRNA pharmaceuticals and drug delivery systems, initially focused on oncology. The company also has a partnership with Ipsen to research and develop novel DsiRNA therapeutics with targeted delivery in oncology and endocrinology.
http://www.dicerna.com

Note: At time of posting there were no jobs on their website, but there was this message: 

Employment

For
interest in future employment opportunities,
please submit your resume to

HRAdmin@dicerna.com.